source Post navigation Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial – GlobeNewswire Even an occasional 30-minute exercise session reduces type 2 diabetes risk factors, study finds – Medical Xpress
